Coverage
-
March 11, 2022
The Second Circuit on Friday agreed with a New York federal court that investors hadn't shown that Bristol-Myers hid information about patients in a clinical trial for a new lung cancer drug, holding that the shareholders failed to allege a material misstatement or omission made by the company.
2 other articles on this case.
View all »